EP1037620A1 - Use of formoterol in medicament for inflammation/allergy in upper airways - Google Patents

Use of formoterol in medicament for inflammation/allergy in upper airways

Info

Publication number
EP1037620A1
EP1037620A1 EP98963701A EP98963701A EP1037620A1 EP 1037620 A1 EP1037620 A1 EP 1037620A1 EP 98963701 A EP98963701 A EP 98963701A EP 98963701 A EP98963701 A EP 98963701A EP 1037620 A1 EP1037620 A1 EP 1037620A1
Authority
EP
European Patent Office
Prior art keywords
formoterol
active ingredient
inflammatory
allergic rhinitis
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98963701A
Other languages
German (de)
French (fr)
Inventor
Carl Göran PERSSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of EP1037620A1 publication Critical patent/EP1037620A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Definitions

  • the invention provides the use of formoterol in the treatment of inflammatory and allergic conditions in the upper airways of human beings.
  • Inflammatory and allergic conditions in the upper airways include conditions such as rhinitis, sinusitis and nasal polyps. Conditions such as these are conventionally treated by corticosteroid nasal sprays. The problem with using corticosteroids to treat these conditions is that it takes some time before they take effect.
  • US-A-4,975,466 to Ciba-Geigy relates to pharmaceutical preparations containing formo- terol or one of its pharmaceutically acceptable salts, especially its semifumarate, for treatment of inflammatory skin diseases.
  • the preparations are mainly used for topical, i.e. dermal, application, to the skin and/or mucous membrane, since formoterol is said to have a very pronounced antiphlogistic (dermally phlogistatic) topically anti-inflammatory, action. More specifically, the preparations are intended for external use on the outer skin, including the conjunctiva of the eyeball, the lips and the genital and anal region.
  • the present invention is directed to the use of formoterol, or pharmaceutically acceptable salts or solvates thereof for manufacturing medicaments suitable for use in the treatment of an inflammatory and or allergic condition in the upper airways of a human being.
  • the active ingredient is formoterol fumarate dihydrate.
  • an active ingredient which is formo- terol, a pharmaceutically acceptable salt or solvate of formoterol, or a solvate of such a salt in the manufacture of a medicament for use in the treatment of an inflammatory and/or allergic condition in the upper airways of a human being.
  • a method of treating a patient suffering from an inflammatory and/or allergic condition in the upper airways which comprises administering to the patient a therapeutically effective amount of the active ingredient, wherein the patient is a human being.
  • composition comp- rising the active ingredient in association with one or more pharmaceutically acceptable diluent, carrier or additive, which composition is for use in the treatment of an inflammatory and/or allergic condition in the upper airways of human beings.
  • Formoterol is an adrenoreceptor agonist which selectively stimulates ⁇ 2 -receptors, with the formula (N-[2-hydroxy-5-[l-hydroxy-2-[[2-(4-methoxyphenyl)-l-methyl-ethyl]-amino]- ethyl]-phenyl]-formamide. It has surprisingly been found to be effective in the treatment of inflammatory and allergic conditions in the upper airways of human beings. Inhaled formoterol has the advantage that it both acts rapidly, usually within minutes, and exerts a prolonged effect of up to 12 hours.
  • Suitable physiologically acceptable salts of formoterol include acid addition salts derived from inorganic and organic acids, for example the chloride, bromide, sulfate, phosphate, maleate, fumarate, tartrate, citrate, benzoate, 4-methoxybenzoate, 2- or 4-hydroxybenzoate, 4-chlorobenzoate, p-toluenesulfonate, methanesulfonate, ascorbate, acetate, succinate, lactate, glutarate, gluconate, tricarballylate, hydroxynaphthalene-carboxylate oroleate salts or solvates thereof.
  • the active ingredient is preferably formoterol fumarate, especially the dihydrate.
  • Formoterol pharmaceutically acceptable salts and solvates of formoterol, and solvates of such salts can be prepared by the methods described in US-A-5,434,304 to Astra and DE- A-2,305,092 to Yamanouchi.
  • the preferred daily dose of the active ingredient is from 5 to 250 nmol (preferably from 15 to 120 nmol).
  • the active ingredient is formoterol fumarate dihydrate the preferred daily dose is from 3 to 96 ⁇ g, more preferably from 3 to 48 ⁇ g and most preferably from 3 to 24 ⁇ g per day.
  • suitable unit doses include 3, 4.5, 6, 9 and 12 ⁇ g of formoterol fumarate dihydrate.
  • the invention provides a new and surprisingly effective treatment for inflammatory and/or allergic conditions in the upper airways of a human being.
  • the conditions treatable by the invention are preferably in the nose and paranasal sinus. They include
  • the active ingredient is used in admixture with one or more pharmaceutically acceptable additives, diluents or carriers, preferably in an amount of from 50 ⁇ g to 25 mg per dose, more preferably in an amount of from 50 ⁇ g to 10 mg, most preferably in an amount of from 100 to 4000 ⁇ g.
  • suitable diluents or carriers include lactose, dextran, mannitol and glucose.
  • lactose is used, especially as the monohydrate.
  • the active ingredient used in the invention is preferably in the form of a dry powder, more preferably a finely divided, e.g. amicronized, dry powder, e.g. having a mass median diameter of less than 10 ⁇ m, for example from 1 to 5 ⁇ m, most preferably an agglomerated micronized dry powder. Preferably at least 90% of the powder particles have a size below 15 ⁇ m.
  • the finely divided active ingredients may be in the form of an ordered mixture with one or more pharmaceutically acceptable additives, diluents or carriers.
  • An ordered mixture is the combination of a finely divided active ingre- dominant with coarse particles of a pharmaceutically acceptable additive, diluent and/or carrier.
  • the ingredients used in the invention can be obtained in these preferred forms using methods known to those skilled in the art.
  • EXAMPLE 1 10 parts of formoterol fumarate dihydrate was mixed with 990 parts of lactose mono- hydrate. The blend was micronized using a high pressure air jet mill and then conditioned using the process of EP-A-717616. The mixture was then spheronised using the process of EP-A-721331, divided into parts, each of which were filled into the storage compartment of a Turbuhaler fitted with a dosing disc such that it administered, when activated, a unit dose of 6 ⁇ g.

Abstract

The invention provides the use of an active ingredient which is formoterol, a pharmaceutically acceptable salt or solvate of formoterol, or a solvate of such a salt in the manufacture of a medicament for use in the treatment of an inflammatory and/or allergic condition in the upper airways of a human being.

Description

USE OF FORMOTEROL IN MEDICAMENT FOR INFLAMMATION/ALLERGY IN UPPER AIRWAYS
FIELD OF THE INVENTION
The invention provides the use of formoterol in the treatment of inflammatory and allergic conditions in the upper airways of human beings.
BACKGROUND OF THE INVENTION
Inflammatory and allergic conditions in the upper airways include conditions such as rhinitis, sinusitis and nasal polyps. Conditions such as these are conventionally treated by corticosteroid nasal sprays. The problem with using corticosteroids to treat these conditions is that it takes some time before they take effect.
The use of a beta-2-adrenostimulant, fenoterol, to treat seasonal allergic rhinitis has been investigated. It was found that it had an insignificant effect upon nasal hypersecretion and nasal blockage caused by the rhinitis (Borum et al, Allergy 42, (1987), pp. 141-145).
US-A-4,975,466 to Ciba-Geigy relates to pharmaceutical preparations containing formo- terol or one of its pharmaceutically acceptable salts, especially its semifumarate, for treatment of inflammatory skin diseases. The preparations are mainly used for topical, i.e. dermal, application, to the skin and/or mucous membrane, since formoterol is said to have a very pronounced antiphlogistic (dermally phlogistatic) topically anti-inflammatory, action. More specifically, the preparations are intended for external use on the outer skin, including the conjunctiva of the eyeball, the lips and the genital and anal region. There is no information about use of formoterol or preparations thereof for alleviating inflammatory and/or allergic conditions in the upper airways. C. Advenier et al, Br. J. Pharmacol., 105 (1995), pp. 792-798 relates to the effects of the β 2 -adrenoceptor agonists, salbutamol and formoterol, on the increase of micro-vascular permeability induced by histamine or bradykinin in guinea-pig airways. In the nasal mucosa, only salbutamol in doses of 30 μg/kg showed a significant inhibitory effect against histamine whereas formoterol 10 μg/kg significantly increased the effects of histamine in a dramatic manner. Therefore, Advenier et al strongly indicates that use of formoterol in the treatment of inflammatory and/or allergic conditions in the upper airways should be avoided.
Accordingly mere is a need for an effective treatment which has a faster onset time and a long duration.
SUMMARY OF THE INVENTION
The present invention is directed to the use of formoterol, or pharmaceutically acceptable salts or solvates thereof for manufacturing medicaments suitable for use in the treatment of an inflammatory and or allergic condition in the upper airways of a human being.
According to a preferred embodiment of the invention, the active ingredient is formoterol fumarate dihydrate.
DETAILED DESCRIPTION OF THE INVENTION
According to the invention there is provided the use of an active ingredient which is formo- terol, a pharmaceutically acceptable salt or solvate of formoterol, or a solvate of such a salt in the manufacture of a medicament for use in the treatment of an inflammatory and/or allergic condition in the upper airways of a human being.
According to the invention there is also provided a method of treating a patient suffering from an inflammatory and/or allergic condition in the upper airways which comprises administering to the patient a therapeutically effective amount of the active ingredient, wherein the patient is a human being.
According to the invention there is further provided a pharmaceutical composition comp- rising the active ingredient in association with one or more pharmaceutically acceptable diluent, carrier or additive, which composition is for use in the treatment of an inflammatory and/or allergic condition in the upper airways of human beings.
Formoterol is an adrenoreceptor agonist which selectively stimulates β2-receptors, with the formula (N-[2-hydroxy-5-[l-hydroxy-2-[[2-(4-methoxyphenyl)-l-methyl-ethyl]-amino]- ethyl]-phenyl]-formamide. It has surprisingly been found to be effective in the treatment of inflammatory and allergic conditions in the upper airways of human beings. Inhaled formoterol has the advantage that it both acts rapidly, usually within minutes, and exerts a prolonged effect of up to 12 hours.
Suitable physiologically acceptable salts of formoterol include acid addition salts derived from inorganic and organic acids, for example the chloride, bromide, sulfate, phosphate, maleate, fumarate, tartrate, citrate, benzoate, 4-methoxybenzoate, 2- or 4-hydroxybenzoate, 4-chlorobenzoate, p-toluenesulfonate, methanesulfonate, ascorbate, acetate, succinate, lactate, glutarate, gluconate, tricarballylate, hydroxynaphthalene-carboxylate oroleate salts or solvates thereof. The active ingredient is preferably formoterol fumarate, especially the dihydrate.
Formoterol, pharmaceutically acceptable salts and solvates of formoterol, and solvates of such salts can be prepared by the methods described in US-A-5,434,304 to Astra and DE- A-2,305,092 to Yamanouchi.
The preferred daily dose of the active ingredient is from 5 to 250 nmol (preferably from 15 to 120 nmol). When the active ingredient is formoterol fumarate dihydrate the preferred daily dose is from 3 to 96 μg, more preferably from 3 to 48 μg and most preferably from 3 to 24 μg per day. Examples of suitable unit doses include 3, 4.5, 6, 9 and 12 μg of formoterol fumarate dihydrate.
The invention provides a new and surprisingly effective treatment for inflammatory and/or allergic conditions in the upper airways of a human being. The conditions treatable by the invention are preferably in the nose and paranasal sinus. They include
- seasonal allergic rhinitis which is pollinosis caused by pollens from ragweed, birch, grass, cedar or other plants
- perennial allergic rhinitis caused by e.g. dust mites (Dermatophagoides pteronyssinus and D. farinae), cockroaches and mammals such as cats, dogs and horses
- perennial non-allergic rhinitis
- nasal polyps, as well as prevention of post surgical nasal polyps
- chronic sinusitis
- recurrent sinusitis and - hypertrophic adenoids.
Preferably the active ingredient is used in admixture with one or more pharmaceutically acceptable additives, diluents or carriers, preferably in an amount of from 50 μg to 25 mg per dose, more preferably in an amount of from 50 μg to 10 mg, most preferably in an amount of from 100 to 4000 μg. Examples of suitable diluents or carriers include lactose, dextran, mannitol and glucose. Preferably lactose is used, especially as the monohydrate.
The active ingredient used in the invention is preferably in the form of a dry powder, more preferably a finely divided, e.g. amicronized, dry powder, e.g. having a mass median diameter of less than 10 μm, for example from 1 to 5 μm, most preferably an agglomerated micronized dry powder. Preferably at least 90% of the powder particles have a size below 15 μm. As an alternative to agglomeration the finely divided active ingredients may be in the form of an ordered mixture with one or more pharmaceutically acceptable additives, diluents or carriers. An ordered mixture is the combination of a finely divided active ingre- dient with coarse particles of a pharmaceutically acceptable additive, diluent and/or carrier. The ingredients used in the invention can be obtained in these preferred forms using methods known to those skilled in the art.
The invention will be illustrated by the following examples which are not intended to limit the scope of the invention.
EXAMPLES
EXAMPLE 1 10 parts of formoterol fumarate dihydrate was mixed with 990 parts of lactose mono- hydrate. The blend was micronized using a high pressure air jet mill and then conditioned using the process of EP-A-717616. The mixture was then spheronised using the process of EP-A-721331, divided into parts, each of which were filled into the storage compartment of a Turbuhaler fitted with a dosing disc such that it administered, when activated, a unit dose of 6 μg.
Example 2
20 parts of formoterol fumarate dihydrate was mixed with 980 parts of lactose monohydrate. The blend was micronized using a high pressure air jet mill and then conditioned using the process of EP-A-717616. The mixture was then spheronized using the process of EP-A-721331, divided into parts, each of which were filled into the storage compartment of a Turbuhaler fitted with a dosing disc such that it administered, when activated, a unit dose of 12 μg.

Claims

1. Use of an active ingredient which is formoterol, a pharmaceutically acceptable salt or solvate of formoterol, or a solvate of such a salt in the manufacture of a medicament for use in the treatment of an inflammatory and/or allergic condition in the upper airways of a human being.
2. Use according to claim 1, wherein the active ingredient is formoterol fumarate dihydrate.
3. Use according to claim 1 or 2, wherein the inflammatory and/or allergic condition is selected from the group consisting of seasonal allergic rhinitis, perennial allergic rhinitis, perennial non-allergic rhinitis, nasal polyps, chronic sinusitis, recurrent sinusitis and hypertrophic adenoids.
4. Use according to any previous claim, wherein the active ingredient is a finely divided dry powder, preferably an agglomerated micronized dry powder.
5. Use according to claim 4, wherein the finely divided dry powder has a mass median diameter of less than 10 ╬╝m, preferably in the range of from 1 to 5 ╬╝m.
6. Use according to any previous claim, wherein the daily dose of the active ingredient is from 5 to 250 nmol, preferably from 15 to 120 nmol.
7. A method of treating a human patient suffering from an inflammatory and/or allergic condition in the upper airways, which comprises administering to the human patient a therapeutically effective amount of an active ingredient which is formoterol, a pharmaceutically acceptable salt or solvate of formoterol, or a solvate of such a salt.
8. The method according to claim 7, wherein the active ingredient is formoterol fumarate dihydrate.
9. The method according to claim 7 or 8, wherein the inflammatory and/or allergic condition is selected from the group consisting of seasonal allergic rhinitis, perennial allergic rhinitis, perennial non-allergic rhinitis, nasal polyps, chronic sinusitis, recurrent sinusitis and hypertrophic adenoids.
10. A pharmaceutical composition comprising an active ingredient which is formoterol, a pharmaceutically acceptable salt or solvate of formoterol, or a solvate of such a salt in admixture with a pharmaceutically acceptable diluent, carrier and/or additive, which composition is for use in the treatment of an inflammatory and/or allergic condition in the upper airways of a human being.
11. The pharmaceutical composition according to claim 10, wherein the active ingredient is formoterol fumarate dihydrate.
12. The pharmaceutical composition according to any one of claims 10 or 11, wherein the active ingredient is a finely divided dry powder, preferably an agglomeratedmicronized dry powder or an ordered mixture.
13. The pharmaceutical composition according to claim 12, wherein the finely divided dry powder has a mass median diameter of less than 10 ╬╝m, preferably in the range of from 1 to 5 ╬╝m.
14. The pharmaceutical composition according to any one of claims 10 to 13, wherein the dose of active ingredient in admixture with a pharmaceutically acceptable diluent, carrier and/or additive, lies in the range of from 50 ╬╝g to 25 mg, preferably from 100 ╬╝g to 4 mg.
15. The pharmaceutical composition according to any one of claims 10 to 14, wherein the inflammatory and/or allergic condition is selected from the group consisting of seasonal allergic rhinitis, perennial allergic rhinitis, perennial non-allergic rhinitis, nasal polyps, chronic sinusitis, recurrent sinusitis and hypertrophic adenoids.
EP98963701A 1997-12-12 1998-12-10 Use of formoterol in medicament for inflammation/allergy in upper airways Withdrawn EP1037620A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9704644 1997-12-12
SE9704644A SE9704644D0 (en) 1997-12-12 1997-12-12 New use
PCT/SE1998/002278 WO1999030703A1 (en) 1997-12-12 1998-12-10 Use of formoterol in medicament for inflammation/allergy in upper airways

Publications (1)

Publication Number Publication Date
EP1037620A1 true EP1037620A1 (en) 2000-09-27

Family

ID=20409370

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98963701A Withdrawn EP1037620A1 (en) 1997-12-12 1998-12-10 Use of formoterol in medicament for inflammation/allergy in upper airways

Country Status (5)

Country Link
EP (1) EP1037620A1 (en)
JP (1) JP2002508319A (en)
AU (1) AU1897199A (en)
SE (1) SE9704644D0 (en)
WO (1) WO1999030703A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9903995D0 (en) * 1999-11-03 1999-11-03 Astra Ab New combination
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
WO2003063843A1 (en) * 2002-02-01 2003-08-07 Astrazeneca Ab Composition for inhalation
TW200510277A (en) 2003-05-27 2005-03-16 Theravance Inc Crystalline form of β2-adrenergic receptor agonist
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
ES2265276B1 (en) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. DERIVATIVES OF 4- (2-AMINO-1-HYDROXYETHYL) Phenol as agonists of the BETA2 ADRENERGIC RECEIVER.
ES2306595B1 (en) 2007-02-09 2009-09-11 Laboratorios Almirall S.A. NAPADISYLATE SALT OF 5- (2 - ((6- (2,2-DIFLUORO-2-PHENYLETOXI) HEXIL) AMINO) -1-HYDROXYETHYL) -8-HYDROXYCHINOLIN-2 (1H) -ONE AS ADRENERGIC RECEIVER AGONIST BETA2 .
ES2320961B1 (en) 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. DERIVATIVES OF 4- (2-AMINO-1-HYDROXYETHYL) PHENOL AS BETA2 ADRENERGIC RECEIVER AGONISTS.
EP2096105A1 (en) 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
ITRM20110083U1 (en) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire PLATE FOR THE CONSTRUCTION OF TRUCKS FOR AIRPLANES
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2592077A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
SG11201504452WA (en) 2012-12-18 2015-07-30 Almirall Sa New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activity
TWI643853B (en) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH β2 ADRENERGIC RECEPTOR AGONIST AND M3 MUSCARINIC RECEPTOR ANTAGONIST ACTIVITIES
TWI641373B (en) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 SALTS OF 2-AMINO-1-HYDROXYETHYL-8-HYDROXYQUINOLIN-2(1H)-ONE DERIVATIVES HAVING BOTH MUSCARINIC RECEPTOR ANTAGONIST AND β2 ADRENERGIC RECEPTOR AGONIST ACTIVITIES
TW201517906A (en) 2013-07-25 2015-05-16 Almirall Sa Combinations comprising MABA compounds and corticosteroids
TW201617343A (en) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 New bicyclic derivatives having [beta]2 adrenergic agonist and M3 muscarinic antagonist activities

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ298169A (en) * 1994-12-22 1999-09-29 Astra Ab Aerosol drug formulation; comprises hydrofluoroalkane propellant, medicament for inhalation and a surfactant
US5668110A (en) * 1995-06-07 1997-09-16 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9930703A1 *

Also Published As

Publication number Publication date
SE9704644D0 (en) 1997-12-12
AU1897199A (en) 1999-07-05
WO1999030703A1 (en) 1999-06-24
JP2002508319A (en) 2002-03-19

Similar Documents

Publication Publication Date Title
WO1999030703A1 (en) Use of formoterol in medicament for inflammation/allergy in upper airways
US9295644B2 (en) Methods and compositions for treating asthma
US8461211B2 (en) Use for budesonide and formoterol
AU2005316687B2 (en) Compositions and methods for pulmonary conditions
EP0871450A1 (en) New combination
CH680983A5 (en)
JP3042866B2 (en) Respiratory disease drug
WO2001070198A1 (en) Stabilized dry powder formulations
JP5492072B2 (en) Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention and / or treatment of asthma exacerbations
AU8135098A (en) New combination of antiasthma medicaments
AU3707202A (en) New use for budesonide and formoterol
MXPA99011676A (en) New combination of antiasthma medicaments

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000712

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: LT PAYMENT 20000712;LV PAYMENT 20000712;MK PAYMENT 20000712;RO PAYMENT 20000712;SI PAYMENT 20000712

17Q First examination report despatched

Effective date: 20010516

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020820